1	Ultrarare Variants in DNA Damage Repair Genes in Pediatric Acute-Onset											
2	Neuropsychiatric Syndrome or Acute Behavioral Regression in Neurodevelopmental											
3	Disorders											
4	Denning (it), DNA Dennen Dennin Oener in Acute Debening Democratic											
5 6	Running title: DNA Damage Repair Genes in Acute Benavioral Regression											
7	Janet L. Cunningham ¹ , Jennifer Frankovich ^{2,} Robert A. Dubin ³ , Erika Pedrosa ⁴ , Refia Nur											
8	Baykara ⁴ , Noelle Cathleen Schlenk ⁵ , Shahina B. Maqbool ⁶ , Hedwig Dolstra ⁴ , Jacqueline											
9	Marino ⁴ , Jacob Edinger ⁴ , Julia M. Shea ⁴ , Gonzalo Laje ⁷ , Sigrid M.A. Swagemakers ⁸ , Siam											
10	Sinnadurai ^{8,9} , Peter J. van der Spek ⁸ , Herbert M. Lachman ¹⁰ *											
11 12 12	¹ Department of Medical Sciences, Psychiatry, Uppsala University, Uppsala, Sweden											
13	² Department of Pediatrics, Division of Pediatric Allergy, Immunology, Rheumatology and											
15	Immune Behavioral Health Program, Stanford Children's Health and Stanford University School											
16	of Medicine, Palo Alto, CA, USA											
17	³ Center for Epigenomics / Computational Genomics Core, Albert Einstein College of Medicine											
18	⁴ Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine.											
19	⁵ Stanford Children's Health, PANS Clinic and Research Program, Stanford University School of											
20	Medicine, Stanford, CA, USA.											
21	⁶ Department of Genetics Epigenetics Shared Facility, Albert Einstein College of Medicine											
22	⁷ Department of Psychiatry, Permian Basin, Texas Tech University Health Sciences Center											
23	School of Medicine											
24	⁸ Department of Pathology and Clinical Bioinformatics, Erasmus MC, Rotterdam, Netherlands											
25	⁹ Department of Epidemiology and Health Promotion at the School of Public Health											
26	Medical Center for Postgraduate Education, Warsaw, Poland											
27	¹⁰ Department of Psychiatry and Behavioral Sciences, Department of Medicine, Department of											
28	Genetics, Dominick P. Purpura Department of Neuroscience, Albert Einstein College of											
29	Medicine											
30												

- 31 *corresponding author
- 32 Dr. Herbert Lachman
- 33 Albert Einstein College of Medicine
- 34 Forchheimer 103
- 35 1300 Morris Park Ave.
- 36 Bronx, New York 10461
- 37 Phone: 718-430-2428
- 38 Email: Herb.Lachman@einsteinmed.edu
- 39
- 40

41 Abstract

42 Acute onset of severe psychiatric symptoms or regression may occur in children with premorbid 43 neurodevelopmental disorders, although typically developing children can also be affected. 44 Infections or other stressors are likely triggers. The underlying causes are unclear, but a current 45 hypothesis suggests the convergence of genes that influence neuronal and immunological 46 function. We previously identified 11 genes in Pediatric Acute-Onset Neuropsychiatry Syndrome 47 (PANS), in which two classes of genes related to either synaptic function or the immune system 48 were found. Among the latter, three affect the DNA damage response (DDR): PPM1D, CHK2. 49 and RAG1. We now report an additional 16 cases with mutations in PPM1D and other DDR 50 genes in patients with acute onset of psychiatric symptoms and/or regression that were 51 classified by their clinicians as PANS or another inflammatory brain condition. The genes 52 include clusters affecting p53 DNA repair (PPM1D, ATM, ATR, 53BP1, and RMRP), and the 53 Fanconi Anemia Complex (FANCE, SLX4/FANCP, FANCA, and FANCI). We hypothesize that 54 defects in DNA repair genes, in the context of infection or other stressors, could lead to an increase in cytosolic DNA in immune cells triggering DNA sensors, such as cGAS-STING and 55 AIM2 inflammasomes. These findings could lead to new treatment strategies. 56

57

58 Introduction

59 We recently reported the first whole exome and whole genome sequencing (WES and 60 WGS, respectively) analysis in Pediatric Acute-Onset Neuropsychiatry Syndrome (PANS) in 61 which ultrarare variants were found in 11 genes in 21 cases¹. The genes harboring ultrarare 62 variants (minor allele frequency < 0.001) showed extensive heterogeneity but clustered to those 63 that affect innate and adaptive immunity; PPM1D (3 cases), NLRC4 (4 cases), RAG1 (3 cases), 64 PLCG2, and CHK2, or genes that affect synaptic function; SGCE (2 cases), CACNA1B (2 65 cases), SHANK3 (3 cases), and one case each for GRIN2A, GABRG2, and SYNGAP1. Of the 21 subjects, five were diagnosed with autism spectrum disorder (ASD) before their deterioration 66 67 that met PANS criteria. In addition to ASD, four cases were diagnosed with another 68 neurodevelopmental disorder (NDD), one of whom had Jansen de Vries Syndrome (JdVS), 69 which is caused by truncating mutations in *PPM1D* exons 5 or 6 that cause a gain-of-function effect by suppressing p53 and other proteins involved in the DNA damage repair response 70 (DDR) (e.g., MDM2, ATM, CHK1, CHK2, ATR, and H2AX)²⁻⁶. The high prevalence of PANS 71 superimposed on pre-existing NDD is consistent with the observations of other groups^{7, 8}. 72 73 PANS is thought to be an inflammatory disorder that primarily affects the deep brain grey 74 matter (primarily the basal ganglia but the thalamus and amygdala may be involved in more

extensive cases). This hypothesis is based on the cardinal symptoms of PANS and is supported
by four neuroimaging studies showing the following: swelling of the basal ganglia during the
acute stage, microglial activation in the caudate and globus pallidus, grey/white matter
differences in the basal ganglia, and microstructural changes throughout the brain but most
prominently in the basal ganglia⁹⁻¹².

80 The clinical diagnosis PANS has core symptoms of abrupt onset obsessive-compulsive 81 disorder (OCD) and/or restricted eating (food aversion), with two or more secondary symptoms: anxiety, emotional lability, irritability, rage, cognitive regression, sleep disturbance, sensory 82 83 dysregulation, movement abnormalities, urinary symptoms including new onset dysuria or urinary frequency¹³. While the criteria require 2 secondary symptoms, most patients have 5 to 6 84 secondary symptoms that start abruptly alongside the OCD and/or eating restriction. Autonomic 85 86 instability (POTS, dilated pupils, increased urinary frequency, enuresis) and hypermobility have also been reported as co-morbid with PANS¹³⁻¹⁸. A deterioration in school performance occurs, 87 88 exemplified by the loss of previously learned skills and/or new onset procedural learning challenges presumably relating to the basal ganglia inflammation PANS^{9-12, 19}. Activities of daily 89 90 living, extracurricular activities, and social interactions are severely affected during relapses. 91 PANS can occur in children with or without premorbid ASD or other NDD.

92 For parents, the abrupt onset is a telling feature with a rapid decline in behavior and 93 functioning that is sometimes, literally, overnight or emerging over a period of a week. The 94 course is typically relapsing and remitting, but not all relapses are hyperacute/acute. Relapses 95 are frequently associated with an infection and data in support of a neuroinflammatory etiology 96 for PANS is accumulating. In the subgroup of cases following Streptococcus infections, a range 97 of group A streptococcal (GAS) autoantibodies and antibodies to striatal cholinergic interneurons can be detected^{15, 20-22}. Recently, an increased prevalence of folate receptor alpha 98 autoantibodies associated with cerebral folate deficiency and ASD were detected in PANS²³. 99 100 Additionally, cross-sectional prevalence data show that approximately one-third of patients 101 meeting PANS criteria eventually develop enthesitis-related arthritis (ERA) and/or inflammatory back pain further supporting a role for inflammation in this disorder^{18, 24}. Furthermore, 102 inflammatory/autoimmune disorders are prevalent in first-degree family members^{8, 25, 26}. 103 104 As is true in other rare pediatric rheumatological conditions (including ERA and 105 Sydenham chorea), observational studies in PANS suggest that non-steroidal anti-inflammatory 106 drugs (NSAIDs) and corticosteroids may alleviate symptoms and/or shorten the length of the relapses²⁷⁻²⁹. More potent immunomodulators, such as intravenous immunoglobulin (IVIg) and a 107

108 B-cell inhibitor Rituximab have mixed results, likely due to the genetic heterogeneity and the difficulty in appropriately powering randomized trials in relapsing/remitting conditions^{30, 31}. 109 110 An immune-based etiology is also suggested in some cases of ASD and NDD. 111 especially acute and subacute regression, which have some symptoms that overlap with PANS and respond to immunomodulators³²⁻³⁵. In addition, a strong family history of autoimmune 112 113 disorders is associated with an increased risk for ASD³⁶⁻³⁸. 114 We are interested in identifying genetic factors that underlie the development of PANS 115 and acute behavioral regression using next-generation sequencing. In our original paper, two of 116 the ultrarare variants we found are in genes that affect DDR (PPM1D and CHK2), and one 117 induces DNA breaks (RAG1). RAG1, along with RAG2, codes for endonucleases that induce 118 DNA double-strand breaks responsible for the somatic recombination that generates immune cell diversity in B- and T-lymphocytes^{1, 39, 40}, RAG1/RAG2 also affects NK cell differentiation and 119 plays a role in DNA transposition^{41, 42}. Double-stranded breaks induced by the RAG complex are 120 121 repaired by ATM, a serine/threonine kinase that orchestrates DNA repair at double-strand breaks^{40, 43-45} 122 123 Our overarching aim is to identify genetic variations that converge on common biological

123 Our overarching aim is to identify genetic variations that converge on common biological 124 pathways within the heterogeneous population of children with PANS or acute-onset regression 125 with or without premorbid NDD. Given the findings in our first PANS genetic study, one common 126 pathway is DNA repair. This hypothesis is supported by the findings in this paper in which many 127 other genes involved in DNA repair were identified that may contribute to genetic vulnerability.

128

129 Subjects and Methods

130 Ethical considerations

131 This study was conducted in accordance with the Declaration of Helsinki. Parents signed

132 informed consent approved by the Albert Einstein College of Medicine IRB (2022-14636).

133

134 **Subjects.** The subjects were identified through connections between the senior investigators

and a PANS group called EXPAND, a non-profit European advocacy organization for families of

- 136 children, adolescents, and adults with immune-mediated neuropsychiatric disorders
- 137 (https://expand.care/), through the Neuroimmune Foundation, a non-profit organization
- 138 dedicated to neuroimmune and inflammatory brain conditions (<u>https://neuroimmune.org/about/</u>),
- 139 The Louisa Adelynn Johnson Fund for Complex Disease
- 140 (https://tlajfundforcomplexdisease.com/), and the Jansen de Vries Syndrome Foundation
- 141 (https://jansen-devries.org/). Histories were obtained by the participating physicians and

- 142 confirmed and collated by one of the senior investigators who interviewed every family member
- 143 (H.M.L). The cases met the criteria for PANS with or without co-morbid ASD or NDD, or
- 144 individuals with ASD or other NDDs who had a history of rapid-onset behavioral regression.
- 145

146 Genetic analyses

147 Whole exome sequencing (WES) data was available for six cases (**Table**). WES was carried out 148 by different companies Courtagen Diagnostics Laboratory, GeneDx, Baylor Genetics, and for 149 case 10. WES was conducted locally in the Genetics Core at the Albert Einstein College of 150 Medicine, Epigenetics Shared Facility. For the remaining cases, data was available from 151 commercially available panels: Invitae (Primary Immunodeficiency Panel), NHS North West 152 (NDD panel). The genetic variants for cases 1 and 4-12 were verified using Sanger sequencing 153 (see **Table** and **Supplementary Methods**). A comprehensive description of the library 154 preparation and analysis of sequencing data for the Einstein sample (case 10) can be found in 155 the **Supplementary Methods** section. Parents were genotyped for variants found in all cases 156 except cases 10, and 13-16.

157

158 **Evaluation of Variants**

159 Minor allele frequencies (MAFs) were obtained from the GnomAD database on the UCSC

- 160 Genome Browser (https://genome.ucsc.edu/). The ClinVar database, Combined Annotation-
- 161 Dependent Depletion (CADD), and AlphaMissense were used to predict the pathogenicity of
- 162 mutations⁴⁶⁻⁴⁹. https://www.ncbi.nlm.nih.gov/clinvar/. RNAfold was used to predict the secondary
- structure of RMRP. A detailed explanation is in the **Supplementary Methods** section.
- 164

165 Results

166 Ultrarare variants (MAF <0.001) affecting DNA repair genes were found in 16 cases (10 males

and 6 females; specific sex of cases not included to maintain anonymity) including four families

168 with two or more affected individuals. The identified genes are involved in the p53 repair

- pathway: *PPM1D* (2 cases), *ATM* (5 cases,), *ATR* (2 cases), and *53BP1* (one case) (Figure 1),
- and the Fanconi Anemia Complex (FC): FANCE (2 cases), FANCP/ SLX4 (2 cases), FANCI,
- and *FANCA* (one case each) (Figure 2; see Table for details on all p53 and FC gene variants).
- 172 The FC pathway repairs DNA interstrand crosslinks and interacts with ATM/ATR/p53 DNA
- 173 repair pathways (Figure 2)⁵⁰⁻⁵⁵. In addition, ultrarare variants were found in 32 other genes,
- 174 many of which have effects on DNA repair and innate immune function (see **Supplementary**
- 175 **Table** for details on all additional variants for this and other cases described in this paper).

- 176 STRING was used to show the connections between the DNA repair genes and other variants
- found in this study, which centered around ATM and p53 (**Figure 3**). The cases and genetic
- 178 variants with their potential impact on the phenotypes are described below.
- 179

180 p53 DNA Repair Pathway (PPM1D, ATM, ATR, 53BP1)

181 **PPM1D (Protein phosphatase, Mg2+/Mn2+dependent 1D)**

182 Case 1 has JdVS with a 1:1 mosaicism for a de novo truncating PPM1D variant in exon 6. The 183 patient was diagnosed with mild intellectual disability but was high functioning, requiring minimal 184 support until high school when the patient had an abrupt onset of OCD, anxiety, cognitive 185 regression, insomnia, and psychosis with rapid decline over approximately three weeks. The 186 deterioration coincided with an upper respiratory infection and vasculitis. Further regression 187 occurred with the loss of previously mastered global abilities and eventual development of mutism, which has persisted for several years, unresponsive to psychiatric medications and 188 189 other clinical and behavioral interventions.

- Two additional ultrarare de novo variants were found and are likely pathogenic, one of which is relevant to the DDR hypothesis: a variant in *CSNK1a1*, which codes for Casein Kinase 1Alpha 1, a p53 inhibitor^{56, 57}. Another was found in *SRPK3*, an SRSF Protein Kinase that has no known effect on DDR, although interestingly, expression is inversely correlated with alphasynuclein levels in mouse models of Parkinson's disease⁵⁸. Finally, an inherited ultrarare, nonsense mutation was found in the citrate transporter, *SLC13A5* as well as a splice acceptor variant in *CACNA1S*.
- Case 2 also has a typical JdVS variant (a truncating mutation in *PPM1D* exon 6) and
 was diagnosed with ASD and a learning disability. The patient has periods of abrupt onset
 behavioral regression lasting several days to months, characterized by eating refusal, rage,
 cognitive deficits, loss of previously learned skills, an inability to walk, and enuresis. The most
 severe relapses have occurred following infection with SARS-CoV2 and a Group A
 Streptococcal infection concurrent with shingles.
- 203

204 ATM (Ataxia-telangiectasia mutated or serine/threonine kinase)

Case 3 carries an ultrarare and pathological frameshift mutation in *ATM*. The patient was
typically developing and excelled in school until adolescence when diagnosed with Postural
Orthostatic Tachycardia Syndrome (POTS), irritable bowel syndrome gastroparesis, and
enthesitis-related arthritis. Soon thereafter, an episode of gastroenteritis led to acute-onset
OCD, anxiety, impulsivity, and severe rage; the first of many such episodes. An MRI scan was

negative. Relapses responded to IVIg and steroid bursts; however, due to frequent relapses and
the development of chronic symptoms, a trial of Rituximab was undertaken, which was helpful.
While the patient appeared to respond to immunomodulation, severe symptoms returned when
these therapies were tapered or discontinued. Multiple hospitalizations for uncontrolled
psychiatric symptoms followed. A parent carries the same ATM variant and has a history of
dysautonomia and an inflammatory skin conditions.

Other ultrarare variants found in this patient include a de novo variant in *AHNAK2* and
compound heterozygosity for two ultrarare *CACNA1H* variants. While there are no obvious
connections to DNA repair, AHNAK2 has been implicated in systemic lupus erythematosus
(SLE) in two studies and *CACNA1H* mutations are found in ASD and intellectual disabilities⁵⁹⁻⁶².

Cases 4-7 are a family with four affected children who all carry a pathogenic parental transmitted ATM splice donor mutation. There is a bilneal parental history of severe autoimmune disorders and hypermobile joints, as well as an extended family history of early-onset cancer, and autoimmune disorders. This is consistent with the increased risk of cancer and autoimmune disorders in individuals with loss of function mutations in *ATM*⁶³⁻⁶⁶.

225 Case 4, the proband, was diagnosed with ASD and experienced a typical PANS 226 relapsing-remitting course with abrupt relapses of OCD, food aversion, anxiety, irritability, 227 impulse control problems, oppositional behaviors, tics, and fatigue. Relapses were commonly 228 coincident with infections and were effectively managed by addressing infections with antibiotics 229 and using IVIg. The proband also has a history of Hashimoto's thyroiditis, joint hypermobility, 230 and consistently low immunoglobulin levels which likely contributed to frequent infections. 231 Alongside the ATM variant, the patient inherited rare and ultrarare variants affecting DNA repair 232 and innate immunity including a likely pathogenic variant in RNASEH2B, which codes for 233 Ribonuclease H2, an enzyme that removes ribonucleotides that have been incorporated into replicating DNA, affecting double-stranded break repair kinetics⁶⁷. Homozygosity for this variant 234 235 leads to Aicardi-Goutières syndrome (AGS), a type I interferonopathy characterized by 236 neurodevelopmental defects and upregulation of type I interferon signaling and neuroinflammation due to the effects of DNA damage^{67, 68}. The patient also has ultrarare 237 238 nonsynonymous variants of unknown significance in RAG2, NOD2, and a 24-base pair 239 microduplication in SP110. Each of these genes has effects on innate immunity, but RAG2 is the only one with a strong connection to DNA repair, as described in the introduction^{1, 39, 40, 69}. An 240 241 NOD2 variant was transmitted from one of the parents. A second ultrarare variant in NOD2 was 242 identified in the other parent (see **Supplementary Table**).

243 Cases 5-7 are siblings to case 4 who were all diagnosed with ASD, dysautonomia, and 244 joint hypermobility. They all have a relapsing-remitting course characterized by abrupt onset 245 OCD, anxiety, emotional lability, increased urinary frequency, oppositional behavior, and 246 reduced social interactions, along with cognitive and behavioral regression. Relapses are 247 typically coincident with infection. Case 5 had an MRI that showed right temporal sclerosis. 248 Cases 6 and 7 have epilepsy, low levels of IgM and IgA, and relapses improve after clearance 249 of infection and treatment with IVIg and/or a corticosteroid burst. Although they were not 250 analyzed by WES, each was analyzed by Sanger sequencing for the variants found in the 251 proband. Each sibling has inherited the ATM variant, and cases 5 and 6, the RNASEH2B 252 variant. They have also inherited one of the two NOD2 variants. 253

254 ATR (Ataxia telangiectasia and rad3-related protein)

255 Cases 8 and 9 are siblings with regressive ASD and a relapsing-remitting course with relapses 256 commonly coincident with infections. They both have a unique, transmitted ultrarare ATR variant 257 of unknown significance. One parent has a history of Hashimoto's thyroiditis and a family history 258 of SLE, and the other parent has a history of joint hypermobility and childhood seizure disorder. 259 ATR is a serine/threonine kinase and DNA damage sensor that functions as a master regulator of the DDR⁷⁰⁻⁷⁴. The proband, case 8, was a typically developing child with hypermobility who 260 261 was well until abrupt behavioral regression occurred following "croup" at which time a diagnosis 262 of ASD was made. The patient subsequently developed a relapsing-remitting course 263 characterized by abrupt onset OCD, aggression, and mutism. Relapses appeared to be 264 responsive to NSAIDs.

265 The proband's sibling, Case 9, was well until the development of an abrupt behavioral 266 regression and loss of previously achieved milestones following a herpesvirus 6 infection, after 267 which a diagnosis of ASD was made. The patient also has a relapsing-remitting course 268 characterized by abrupt onset of OCD, restricted eating, rage, and depression. Relapses are 269 typically coincident with infections. Symptoms typically respond to glucocorticoid bursts. MRI 270 showed atrophy of the hippocampus, amygdala, caudate, and putamen. WES analysis of both 271 cases 8 and 9 also revealed several other ultrarare variants of interest: NLRX1, CENPJ, 272 CACNA1S, DBH, and CLPB. The most interesting from the DNA repair perspective is a 273 pathogenic frameshift mutation in CENPJ, which codes for centromere protein J. Centromere 274 regulation is critical for maintaining genomic stability, and defects lead to aberrant mitosis and activation of the cGAS-STING pathway^{74, 75}. It is interesting to note that biallelic mutations in 275 276 CENPJ and ATR can both cause Seckel syndrome, which is associated with cell-cycle

checkpoint signaling abnormalities^{76, 77}. Another variant was found in *NLRX1*, which codes for a

key player in the innate immune response that regulates NF-κB expression and has been
implicated in autoimmune and inflammatory diseases⁷⁸⁻⁸¹. A third sibling is typically developing
and did not inherit the *ATR* variant but carries the *CENPJ*, *CACNA1S*, and *CLPB* variants.
Thus, the two affected siblings with ASD and acute-onset neuropsychiatric symptoms have

- 282 ultrarare variants in two genes that affect DNA repair, ATR, and CENPJ, as well as NLRX1
- 283 DBH, CACNA1S, and CLPB.
- 284

277

285 **53BP1 (Tumor suppressor p53-binding protein 1)**

286 Case 10 has a history of developmental delay, and experienced severe regression as a young 287 child characterized by loss of the ability to walk, loss of verbal skills, and new-onset enuresis. 288 Upon WES, we found an ultrarare missense mutation in 53BP1, a p53-binding protein that regulates DDR⁸²⁻⁸⁴. A preceding infection to initial deterioration was not ascertainable. 289 290 However, the patient developed a relapsing-remitting course with relapses (abrupt onset of 291 OCD, eating refusal, severe rage, and oppositional behavior) coincident with infections with 292 improvement following treatment infections with antibiotics. The patient also developed 293 Hashimoto's thyroiditis, scoliosis, joint hypermobility, and gastroparesis. A parent has a history 294 of Raynaud's and fibromyalgia, and there is a family history of thyroid disease and Parkinson's 295 Disease. Parents have not been genotyped. In addition to 53BP1, several other ultrarare 296 variants were found that could be playing a role in the clinical state via DNA repair. One is 297 *MED1*, which codes for a mediator complex protein that plays a major role in homologous 298 recombination, base excision repair, the maintenance of genomic stability, and p53-dependant apoptosis⁸⁵. It has also been implicated in SLE⁸⁶. Another is *KMT2D*, which codes for a histone 299 300 methyltransferase that plays a role in DNA repair and has been implicated in autoimmune 301 disorders^{87, 88}. Finally, we found a nonsense mutation in *MTO1*, which regulates oxidative phosphorylation and has been found to affect DNA repair and recombination in yeast ^{89, 90}. 302

303

304 Fanconi Anemia Complex (FANCE, FANCP/SLX4, FANCA, and FANCI)

305 FANCE (Fanconi anemia complementation group E)

306 Cases 11 and 12, a sibling pair with common variable immune deficiency (CVID) and acute

307 onset of neuropsychiatric symptoms; both carry an ultrarare missense mutation in *FANCE*.

- 308 Case 11 met the diagnostic criteria for PANS, characterized by a relapsing-remitting course of
- 309 abrupt onset OCD, anxiety, and rage. Episodes were commonly coincident with group A
- 310 streptococcal infection and other infections and always improved after treating the infection

311 followed by a corticosteroid burst. IVIg (aimed to treat the underlying CVID) was associated with 312 a reduced frequency of relapses but did not reduce the severity of relapses. Case 12 was 313 diagnosed with ASD as a child after the abrupt loss of speech and eye contact following an 314 infection. The patient regained eye contact and sociability, but apraxia of speech continued. He 315 regressed again later in childhood and soon thereafter was diagnosed with PANS characterized 316 by abrupt onset of OCD, anxiety, aggression (self-injurious behavior and property destruction), 317 and tics, which improved after treating the infection followed by corticosteroids. The patient 318 subsequently developed acute onset dysarthria and mutism and further evaluation revealed 319 CSF pleocytosis, intracranial hypertension, and GAD antibodies (three times the upper limit of 320 normal). Subsequent relapses responded to addressing infection followed by a corticosteroid 321 burst. Relapse frequency (but not severity) was reduced following the introduction of IVIg to 322 treat CVID. Due to a chronic progressive course, Rituximab was added, which was followed by 323 documented improvements by the speech pathologist that were lost when B cells were 324 repopulated (the speech pathologist was blinded to treatments and B cell repopulation). 325 Consequently, Rituximab was scheduled quarterly. The clinical trajectory improved but 326 deteriorations coincident with infections occurred, so Leflunomide was added as adjunct therapy 327 which has led to further stabilization for 2 years. There is a positive history of an inflammatory 328 skin disease on both sides of the family and a family history of an immunodeficiency syndrome, 329 arthritis, lupus-related autoantibodies, recurrent sepsis, and recurrent septic joints. Both cases 330 carry an ultrarare variant of unknown significance in VPS13B. Case 11 carries a maternally 331 transmitted NOD2 variant that has been described as a risk allele in Crohn's disease^{90, 91}. Case 332 12 carries another ultrarare, pathogenic, novel variant involved in the DNA repair gene, 333 THRAP3, which codes for thyroid hormone receptor-associated protein 3, an RNA processing 334 factor involved in ATR kinase-dependent DDR and the expression of several DNA repair proteins, including FANCL 92, 93. 335

336

337 FANCI (Fanconi anemia, complementation group I)

Case 13 is a neurotypical child who developed a sudden onset of OCD, fatigue, restricted
eating, severe anxiety, enuresis, and insomnia following an upper respiratory infection.
Autoimmune thyroiditis was diagnosed based on having high titers of anti-thyroid peroxidase
and anti-thyroglobulin antibodies, an elevated TSH, and an ultrasound. A nonsense mutation in *FANCI* was identified. There was a partial response to intravenous glucocorticoids, IVIg, and
Rituximab. Case 11 also carries ultrarare variants in two other genes that affect DNA repair.
One is a non-synonymous variant in another FC gene, *FANCP/SLX4*, which may be a benign

345 variant. However, cases 14 and 15 also have an ultrarare variant in this gene (see below). The

other is a variant in the DNA repair gene, *LIG4*, which codes for DNA Ligase IV, a key enzyme

- involved in repairing DNA double-strand breaks through non-homologous end joining and
- 348 sealing DNA breaks that occur during V(D)J recombination^{94, 95}. *LIG4* mutations cause
- 349 autoimmune and immunodeficiency disorders^{95, 96}.
- 350

351 FANCP/SLX4 Fanconi anemia, complementation group P/Structure-Specific

352 endonuclease subunit)

353 Cases 14 and 15 are siblings diagnosed with CVID who carry a pathogenic mutation in 354 TNFRSF13B, which is one of the more common variants found in immune deficiencies^{97, 98}. The 355 same variant has been found in several other PANS cases (unpublished observations). They 356 also share an ultrarare variant in FANCP/SLX4, but the relatively low CADD score suggests that 357 the gene alone is not sufficient to explain the severe clinical presentation. Case 14 has a history 358 of acute neuropsychiatric decompensation consistent with PANS, who initially responded to 359 treatment with corticosteroid bursts and IVIg and further stabilized on Anakinra. Case 15 initially 360 presented with anxiety but has regressed substantially, developing a seizure disorder and 361 autoimmune encephalitis (AE) that has partially responded to Rituximab, glucocorticoids, and 362 IVIg. Anakinra has not been effective. MRI indicates atrophy. The siblings also have an ultrarare 363 missense mutation adjacent to a splice acceptor site in DOCK8, which has been implicated in immune deficiency and autoimmune disorders^{65, 99}. Both also share a variant in *MEFV* (pyrin), 364 an inflammasome regulator gene that is commonly mutated in autoinflammatory disorders¹⁰⁰⁻¹⁰³. 365 366 Finally, they both have an ultrarare variant in *RMRP*, a noncoding RNA that functions as the 367 RNA component of mitochondrial RNA processing endoribonuclease. This is a very intriguing candidate according to our DNA repair model as it acts as an inhibitor of p53^{104, 105}. A 368 369 comparison between wild-type and mutant alleles using RNAfold shows differences in the

- 370 secondary structure, suggesting that it could be functional (**Supplementary Figure**).
- 371

372 FANCA Fanconi Anemia, Complementation Group A

Case 16 is a previously healthy and neurotypical child who presented with abrupt-onset OCD,
eating restriction, severe irritability, hyperactivity, aggression, mood swings, sensory
amplification, and headaches. Physical exams showed truncal instability, subtle choreiform
movements, folliculitis, and findings consistent with enthesitis and arthritis (confirmed on joint
ultrasound). Labs indicate persistently elevated vasculitis markers (high vWF Ag and D-dimers
after COVID-19), persistently elevated C4, and persistent microcytic anemia thought to be

379 secondary to chronic inflammation. The patient has had a secondary progressive course with 380 relapses coincident with infections (influenza, mycoplasma, COVID-19, and sinusitis) with partial 381 improvement after bacterial infections were treated. Psychotropics and CBT have been 382 minimally helpful. The patient did not tolerate oral or IV steroids, IVIG, or immunomodulation 383 aimed at treating arthritis and systemic inflammation (e.g., methotrexate, sulfasalazine, and 384 azathioprine). There has been a partial response to NSAIDs, and more recently, a solid 385 trajectory of improvement since introducing colchicine. An ultrarare pathogenic variant 386 (according to AlphaMissense) was found in FANCA. In addition, ultrarare variants were found in 387 five other genes that have effects on innate immune function, but no direct effect on DNA repair. 388 The most important is a pathogenic variant in UNC93B1, a regulator of nucleic acid-sensing toll-389 like receptors (e.g., TLR3, TLR7, and TLR8) and interferon and STING signaling, suggesting a synergistic interaction with FANCA-related DNA repair defects¹⁰⁶⁻¹⁰⁸. The others are ultrarare 390 391 variants of unknown significance in NLRP1, TICAM1, TYK2, and TCN2. NLRP1, TICAM1, and 392 TYK2 have regulatory effects on the innate immune system, including nucleic acid sensing, and have been implicated in autoimmune disorders¹⁰⁹⁻¹¹². 393

First-degree relatives have migraines, recurrent sinusitis, recurrent pancreatitis, and
 spondylarthritis. First-degree family members also have anxiety, OCD, ADHD, and depression.

397 Discussion

398 Sixteen cases were identified with ultrarare variants in protein-coding genes related to p53 and 399 FC DNA repair pathways: PPM1D, ATM, ATR, 53BP1, FANCE, FANCI, FANCP/SLX4, and 400 FANCA. These were often accompanied by additional rare variants related to DNA repair and/or 401 immune deficiencies. Most individuals in this study have an underlying neurodevelopmental 402 disorder, with approximately half diagnosed with ASD. The unifying feature for these cases is 403 the distinct, acute onset change in behavior, severe psychiatric symptoms, and loss of function 404 in association with infections and other stressors. Many cases have symptoms consistent with 405 PANS, while others had acute, severe neuropsychiatric decompensation (e.g., mutism, 406 behavioral regression, loss of previously learned skills, cognitive dysfunction) that did not meet 407 clinical criteria for PANS. Co-morbid inflammatory conditions were common, including vasculitis 408 signs (n=2), enthesitis and/or arthritis (n=3), thyroiditis, and/or elevated thyroid antibodies (n=3). 409 Inflammatory conditions were also common among first-degree family members. Three cases 410 had abnormal MRI scans (cases 5, 9, and 15), and one (case 3) had a normal study. 411 Pleocytosis and moderately elevated anti-GAD antibodies were found in case 12. Clinical 412 improvement was observed in most cases following the resolution of infections and the

413 application of immunomodulation (NSAIDS, corticosteroids, IVIg, Rituximab, colchicine, etc.).
414 The findings are congruent with our previous work and provide further support for our
415 hypothesis that DNA repair deficits are a vulnerability factor for neuropsychiatric

416

decompensation.

417 The DNA repair hypothesis first emerged from our original genetic analysis in which 418 three out of the five immune genes we identified have strong connections to this process: 419 PPM1D, CHK2, and RAG1¹. The idea that DNA repair deficits underlie PANS and acute 420 decompensation in NDD is novel, although studies linking DDR to behavior have been 421 described. For example, postmitotic genome instability in neurons can lead to behavioral 422 alterations and neurodegenerative disorders, and genetic studies show that DNA repair genes 423 are involved in genetic subgroups of ASD and NDDs including most of the genes described in this report (e.g., PPM1D, ATM, ATR, 53BP1, FANCE, FANCI, and FANCP/SLX4)¹¹³⁻¹²⁰. 424

425 The two major gene families affecting DNA repair described in this paper code for 426 proteins involved in the p53 and FC pathways. So far, between the current study and our 427 previous report, we have found ultrarare variants in five protein-coding genes that directly affect 428 p53: PPM1D, ATM, CHK2, ATR, and 53BP1. Among these genes, pathogenic mutations were 429 found in PPM1D, ATM, and, in our previous study, CHK2. The ultrarare ATR and 53BP1 430 variants described in this paper, however, are variants of unknown significance that will require replication and functional validation. Remarkably, we also found an ultrarare variant in the long 431 non-coding RNA gene, *RMRP*, a p53 inhibitor^{104, 105}. *RMRP* expression is induced by immune 432 433 activators and is increased in autoimmune/autoinflammatory disorders¹²¹. As described in the 434 results section, structural differences between the mutant and wild-type alleles were predicted 435 by RNAfold, but again, functional validation would be needed to determine whether the RMRP 436 variant we identified affects p53 function and DNA repair.

Ultrarare variants were found in four different FC genes: *FANCE, FANCP/SLX4, FANCI,*and *FANCA*. Among these, all are predicted to be pathogenic, except the *FANCP/SLX4*variants. However, the fact that two different ultrarare variants were found in this gene in three
cases from two families increases the likelihood they are playing a role. Interestingly, FC
proteins interact with components of the p53 DDR pathway, including ATM and ATR (Figure
2)¹²²⁻¹²⁵.

Some researchers have suggested that autoimmune and/or autoinflammatory processes underlie the development of behavioral regression in PANS and in a subgroup of individuals with ASD^{35, 126-128}. Impaired DDR may be one mechanism for these associations as it can lead to leakage of nuclear DNA into the cytosol, which can trigger the cGAS-STING pathway, a key

447 component of the type I interferon (IFN-I) anti-viral innate immune response, especially following 448 an infectious disease trigger^{66, 129-131}. Mitochondrial DNA breaks and oxidized mitochondrial DNA 449 released into the cytosol can also trigger cGAS-STING¹³²⁻¹³⁴. AIM2 inflammasome signaling, 450 which leads to the induction of IL-1β and IL-18, is also triggered by cytosolic DNA^{135, 136}.

451 Physiological activation of cGAS-STING is central for the response to foreign viral DNA, 452 and perhaps viral RNA as well⁴¹. However, studies show that over-activation can lead to autoimmune, autoinflammatory, and neurodegenerative disorders¹³⁷⁻¹⁴⁰. For example, increased 453 454 IFN-I responses mediated by cGAS-STING due to abnormal clearance of cytosolic DNA and 455 RNA have been implicated in the pathogenesis of autoimmune disorders including SLE and aggressive rheumatoid arthritis¹⁴¹⁻¹⁴⁴. Circulating type I IFN levels are elevated in approximately 456 50% of patients with SLE and IFN receptor inhibition is an approved therapy^{145, 146}. A substantial 457 fraction of SLE patients have neuropsychiatric symptoms^{147, 148}. It has also been proposed that 458 459 some neurodegenerative disorders involve cGAS-STING signaling, including Alzheimer's 460 Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD), and multiple sclerosis (MS)¹⁴⁹⁻¹⁵¹. Markers for neurodegenerative disorders are 461 462 elevated in 27% of patients with psychiatric disease preselected for suspected immunological 463 involvement and phenotypes including catatonia, agitation, and acute onset of symptoms similar 464 to the cases described here, although the genetic data is not available 465 (https://doi.org/10.21203/rs.3.rs-3491787/v1). Early immunological interventions may mitigate

some damage, but this needs to be confirmed in clinical trials. However, other forms of damagemay accumulate over time that are not responsive to immunological interventions.

In addition to nuclear DNA, disruption of mitochondrial integrity can also lead to the
release of mitochondrial DNA into the cytoplasm, which is a potent cGAS-STING trigger¹³²⁻¹³⁴. A
few of the genes described in this report have effects on mitochondria (e.g., *MTO1, SLC13A5, RMRP*). Some FC proteins also regulate mitochondrial DNA replication fork stability that can
activate the mtDNA-dependent cGAS/STING response when dysfunctional, and FANCI has
been found to regulate PRKN-mediated mitophagy^{152, 153}.

A large number of cases had more than one DNA repair gene mutation. This could be due to ascertainment bias since most of the cases we studied had severe symptoms and accompanying neurodevelopmental problems, which could have prompted genetic testing by their physicians. Gene panels rather than WGS per se were performed in many cases, which could cause ascertainment bias due to the selection of genes represented on the commercially available gene panels (**Table**). However, the histories of autoimmune disorders from both parents in many cases suggest true bilineal inheritance of risk variants.

- 481 The current paper explores a genetic subgroup linked to impaired DNA repair with acute
- 482 onset of severe psychiatric symptoms or regression in children associated with infections. It is
- 483 important to note that non-infectious cellular stressors can also induce DNA damage and
- 484 activate cGAS-STING, such as cellular injury, heat shock, and oxidative stress^{154, 155}. In
- 485 addition, recent studies suggest that faulty DNA repair could disrupt several cellular processes
- 486 beyond an innate immune response, such as autophagy, senescence, and apoptosis¹⁵⁶⁻¹⁵⁸.
- 487 Clinically, if our findings are confirmed, they could lead to specific diagnostic tools and
- 488 new treatments for infection-associated psychiatric episodes and behavioral decompensation in
- 489 PANS, ASD, and other NDDs in those with DNA repair mutations, targeting putative over-
- 490 stimulated immune pathways (e.g., type I interferons and AIM2 inflammasomes). To validate our
- 491 findings, more studies are needed to integrate longitudinal clinical data, genetics, and
- 492 immunophenotypes. Functional studies on immune cells from patients, and microglia from
- 493 animal models and induced pluripotent stem cells (iPSCs) are also needed. Studies using iPSC-
- 494 derived microglia with genetic variants in DNA repair genes are ongoing.
- 495

References

496 1. Trifiletti, R. *et al.* Identification of ultra-rare genetic variants in pediatric acute onset
497 neuropsychiatric syndrome (PANS) by exome and whole genome sequencing. *Sci. Rep.* 12,
498 11106-3 (2022).

2. Bhattacharya, D., Hiregange, D. & Rao, B. J. ATR kinase regulates its attenuation via PPM1D
phosphatase recruitment to chromatin during recovery from DNA replication stress signalling. *J. Biosci.* 43, 25-47 (2018).

3. Jansen, S. *et al.* De Novo Truncating Mutations in the Last and Penultimate Exons of PPM1D
Cause an Intellectual Disability Syndrome. *Am. J. Hum. Genet.* **100**, 650-658 (2017).

504 4. Gräf, J. F. *et al.* Substrate spectrum of PPM1D in the cellular response to DNA double-strand 505 breaks. *iScience* **25**, 104892 (2022).

506 5. Nahta, R. & Castellino, R. C. Phosphatase magnesium-dependent 1 δ (PPM1D),
507 serine/threonine protein phosphatase and novel pharmacological target in cancer. *Biochem.*508 *Pharmacol.* 184, 114362 (2021).

509 6. Zekavat, S. M. *et al.* TP53-mediated clonal hematopoiesis confers increased risk for incident 510 atherosclerotic disease. *Nat. Cardiovasc. Res.* **2**, 144-158 (2023).

511 7. Jyonouchi, H., Geng, L. & Davidow, A. L. Cytokine profiles by peripheral blood monocytes are
512 associated with changes in behavioral symptoms following immune insults in a subset of ASD
513 subjects: an inflammatory subtype? *J. Neuroinflammation* **11**, 187-2 (2014).

- 8. O'Dor, S. L. *et al.* A Survey of Demographics, Symptom Course, Family History, and Barriers
 to Treatment in Children with Pediatric Acute-Onset Neuropsychiatric Disorders and Pediatric
 Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections. *J. Child*Adolesc. Psychopharmacol. 32, 476-487 (2022).
- 518 9. Giedd, J. N., Rapoport, J. L., Garvey, M. A., Perlmutter, S. & Swedo, S. E. MRI assessment
 519 of children with obsessive-compulsive disorder or tics associated with streptococcal infection.
 520 Am. J. Psychiatry 157, 281-283 (2000).
- 521 10. Kumar, A., Williams, M. T. & Chugani, H. T. Evaluation of basal ganglia and thalamic
 522 inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with
 523 streptococcal infection and tourette syndrome: a positron emission tomographic (PET) study
 524 using 11C-[R]-PK11195. *J. Child Neurol.* **30**, 749-756 (2015).
- 525 11. Cabrera, B. *et al.* Neuroanatomical features and its usefulness in classification of patients 526 with PANDAS. *CNS Spectr.* **24**, 533-543 (2019).
- 527 12. Zheng, J. *et al.* Association of Pediatric Acute-Onset Neuropsychiatric Syndrome With
 528 Microstructural Differences in Brain Regions Detected via Diffusion-Weighted Magnetic
 529 Resonance Imaging. *JAMA Netw. Open* **3**, e204063 (2020).
- 530 13. Chang, K. *et al.* Clinical evaluation of youth with pediatric acute-onset neuropsychiatric
 531 syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. *J. Child*532 *Adolesc. Psychopharmacol.* 25, 3-13 (2015).
- 533 14. Vreeland, A. *et al.* Neuroinflammation in Obsessive-Compulsive Disorder: Sydenham
 534 Chorea, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal
 535 Infections, and Pediatric Acute Onset Neuropsychiatric Syndrome. *Psychiatr. Clin. North Am.*536 46, 69-88 (2023).
- 537 15. Vreeland, A. *et al.* Post-infectious inflammation, autoimmunity, and OCD: Sydenham
 538 Chorea, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal
 539 infection (PANDAS), and Pediatric Acute-onset Neuropsychiatric Disorder (PANS). *Dev.*540 *Neurosci.* (2023).
- 541 16. Thienemann, M. *et al.* Clinical Management of Pediatric Acute-Onset Neuropsychiatric
 542 Syndrome: Part I-Psychiatric and Behavioral Interventions. *J. Child Adolesc. Psychopharmacol.*543 27, 566-573 (2017).
- 544 17. Chan, A. *et al.* Children With PANS May Manifest POTS. *Front. Neurol.* **13**, 819636 (2022).
- 545 18. Ma, M. *et al.* Arthritis in children with psychiatric deteriorations: a case series. *Dev.*546 *Neurosci.*, 1 (2023).
- 547 19. Foerde, K. & Shohamy, D. The role of the basal ganglia in learning and memory: insight 548 from Parkinson's disease. *Neurobiol. Learn. Mem.* **96**, 624-636 (2011).

549 20. Swedo, S. E. *et al.* Pediatric autoimmune neuropsychiatric disorders associated with
550 streptococcal infections: clinical description of the first 50 cases. *Am. J. Psychiatry* **155**, 264-271
551 (1998).

- 552 21. Cunningham, M. W. Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive 553 Antigens of Group A Streptococci and their Sequelae. *Microbiol. Spectr.* **7**,
- 554 10.1128/microbiolspec.GPP3-2018 (2019).
- 555 22. Hyman, S. E. PANDAS: Too Narrow a View of the Neuroimmune Landscape. *Am. J.* 556 *Psychiatry* **178**, 5-7 (2021).

23. Wells, L., O'Hara, N., Frye, R. E., Hullavard, N. & Smith, E. Folate Receptor Alpha
Autoantibodies in the Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric
Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)
Population. *Journal of personalized medicine* 14, 166 (2024).

561 24. Frankovich, J. *et al.* Multidisciplinary clinic dedicated to treating youth with pediatric acute562 onset neuropsychiatric syndrome: presenting characteristics of the first 47 consecutive patients.
563 *J. Child Adolesc. Psychopharmacol.* 25, 38-47 (2015).

564 25. Masterson, E. E. & Gavin, J. M. Baseline characteristics of children in the International 565 PANS Registry (IPR) Epidemiology Study. *BMJ Open* **14**, e072743-072743 (2024).

566 26. Chan, A. *et al.* Familial Clustering of Immune-Mediated Diseases in Children with Abrupt567 Onset Obsessive Compulsive Disorder. *J. Child Adolesc. Psychopharmacol.* **30**, 345-346
568 (2020).

569 27. Brown, K. *et al.* Pediatric Acute-Onset Neuropsychiatric Syndrome Response to Oral

570 Corticosteroid Bursts: An Observational Study of Patients in an Academic Community-Based 571 PANS Clinic. J. Child Adolesc. Psychopharmacol. **27**, 629-639 (2017).

572 28. Brown, K. D. *et al.* Effect of Early and Prophylactic Nonsteroidal Anti-Inflammatory Drugs on
573 Flare Duration in Pediatric Acute-Onset Neuropsychiatric Syndrome: An Observational Study of
574 Patients Followed by an Academic Community-Based Pediatric Acute-Onset Neuropsychiatric
575 Syndrome Clinic. J. Child Adolesc. Psychopharmacol. 27, 619-628 (2017).

- 576 29. Spartz, E. J. *et al.* Course of Neuropsychiatric Symptoms After Introduction and Removal of
 577 Nonsteroidal Anti-Inflammatory Drugs: A Pediatric Observational Study. *J. Child Adolesc.* 578 *Psychopharmacol* 27, 652-659 (2017)
- 578 Psychopharmacol. **27**, 652-659 (2017).

579 30. Perlmutter, S. J. *et al.* Therapeutic plasma exchange and intravenous immunoglobulin for 580 obsessive-compulsive disorder and tic disorders in childhood. *Lancet* **354**, 1153-1158 (1999).

- 581 31. Williams, K. A. *et al.* Randomized, Controlled Trial of Intravenous Immunoglobulin for
- 582 Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. *J.* 583 *Am. Acad. Child Adolesc. Psychiatry* **55**, 860-867.e2 (2016).

32. Hart, S. J., Worley, G., Kishnani, P. S. & Van Mater, H. Case Report: Improvement
Following Immunotherapy in an Individual With Seronegative Down Syndrome Disintegrative
Disorder. *Front. Neurol.* 12, 621637 (2021).

- 33. Bey, A. L. *et al.* Subacute Neuropsychiatric Syndrome in Girls With SHANK3 Mutations
 Responds to Immunomodulation. *Pediatrics* 145, e20191490. doi: 10.1542/peds.2019-1490
 (2020).
- 34. Zheng, J. *et al.* Association of Pediatric Acute-Onset Neuropsychiatric Syndrome With
 Microstructural Differences in Brain Regions Detected via Diffusion-Weighted Magnetic
 Resonance Imaging. *JAMA Netw. Open* **3**, e204063 (2020).

35. Malek, M. *et al.* Prednisolone as Adjunctive Treatment to Risperidone in Children With
Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial. *Clin. Neuropharmacol.* 43, 39-45 (2020).

596 36. Mohebalizadeh, M. *et al.* Role of Maternal Immune Factors in Neuroimmunology of Brain 597 Development. *Mol. Neurobiol.* (2023).

598 37. Croen, L. A. *et al.* Family history of immune conditions and autism spectrum and
599 developmental disorders: Findings from the study to explore early development. *Autism Res.*600 **12**, 123-135 (2019).

601 38. Arenella, M. *et al.* Immunogenetics of autism spectrum disorder: A systematic literature 602 review. *Brain Behav. Immun.* **114**, 488-499 (2023).

39. Braams, M., Pike-Overzet, K. & Staal, F. J. T. The recombinase activating genes: architects
of immune diversity during lymphocyte development. *Front. Immunol.* 14, 1210818 (2023).

40. Christie, S. M., Fijen, C. & Rothenberg, E. V(D)J Recombination: Recent Insights in
Formation of the Recombinase Complex and Recruitment of DNA Repair Machinery. *Front. Cell. Dev. Biol.* **10**, 886718 (2022).

- 41. Ni, G., Ma, Z. & Damania, B. cGAS and STING: At the intersection of DNA and RNA virussensing networks. *PLoS Pathog.* **14**, e1007148 (2018).
- 42. Chen, X. *et al.* How mouse RAG recombinase avoids DNA transposition. *Nat. Struct. Mol. Biol.* 27, 127-133 (2020).
- 43. Helmink, B. A. & Sleckman, B. P. The response to and repair of RAG-mediated DNA double-strand breaks. *Annu. Rev. Immunol.* **30**, 175-202 (2012).
- 614 44. Johnston, R. *et al.* Nuclease-independent functions of RAG1 direct distinct DNA damage 615 responses in B cells. *EMBO Rep.*, e55429 (2022).
- 45. Chu, S. H. *et al.* Loss of H3K36 Methyltransferase SETD2 Impairs V(D)J Recombination
 during Lymphoid Development. *iScience* 23, 100941 (2020).

- 46. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the
 deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 47, D886-D894
 (2019).
- 47. Niroula, A. & Vihinen, M. How good are pathogenicity predictors in detecting benign variants? *PLoS Comput. Biol.* **15**, e1006481 (2019).
- 48. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* **46**, 310-315 (2014).
- 49. Cheng, J. *et al.* Accurate proteome-wide missense variant effect prediction with AlphaMissense. *Science* **381**, eadg7492 (2023).
- 50. Ceccaldi, R., Sarangi, P. & D'Andrea, A. D. The Fanconi anaemia pathway: new players and new functions. *Nat. Rev. Mol. Cell Biol.* **17**, 337-349 (2016).
- 51. Jones, M. J. K. & Huang, T. T. The Fanconi anemia pathway in replication stress and DNA crosslink repair. *Cell Mol. Life Sci.* **69**, 3963-3974 (2012).
- 52. Traband, E. L. *et al.* Mitotic DNA Synthesis in Untransformed Human Cells Preserves
 Common Fragile Site Stability via a FANCD2-Driven Mechanism That Requires HELQ. *J. Mol. Biol.* 435, 168294 (2023).
- 634 53. Bona, N. & Crossan, G. P. Fanconi anemia DNA crosslink repair factors protect against
 635 LINE-1 retrotransposition during mouse development. *Nat. Struct. Mol. Biol.* (2023).
- 636 54. Kupculak, M. *et al.* Phosphorylation by ATR triggers FANCD2 chromatin loading and 637 activates the Fanconi anemia pathway. *Cell. Rep.* **42**, 112721 (2023).
- 55. Alcón, P. *et al.* FANCD2-FANCI is a clamp stabilized on DNA by monoubiquitination of
 FANCD2 during DNA repair. *Nat. Struct. Mol. Biol.* 27, 240-248 (2020).
- 56. Xu, W. *et al.* Casein kinase 1α inhibits p53 downstream of MDM2-mediated autophagy and
 apoptosis in acute myeloid leukemia. *Oncol. Rep.* 44, 1895-1904 (2020).
- 57. Liu, X. *et al.* Tumor-derived CK1α mutations enhance MDMX inhibition of p53. *Oncogene*39, 176-186 (2020).
- 58. Seo, M. H. & Yeo, S. Association Between Decreased Srpk3 Expression and Increased
 Substantia Nigra Alpha-Synuclein Level in an MPTP-Induced Parkinson's Disease Mouse
- 646 Model. *Mol. Neurobiol.* **60**, 780-788 (2023).
- 59. Akizuki, S. *et al.* PLD4 is a genetic determinant to systemic lupus erythematosus and
 involved in murine autoimmune phenotypes. *Ann. Rheum. Dis.* **78**, 509-518 (2019).
- 649 60. Wen, L. *et al.* Exome-wide association study identifies four novel loci for systemic lupus
 650 erythematosus in Han Chinese population. *Ann. Rheum. Dis.* **77**, 417-211823. Epub 2017 Dec
 651 12 (2018).

- 652 61. Kessi, M. *et al.* Calcium channelopathies and intellectual disability: a systematic review.
 653 *Orphanet J. Rare Dis.* **16**, 219-0 (2021).
- 654 62. Viggiano, M. *et al.* Contribution of CACNA1H Variants in Autism Spectrum Disorder 655 Susceptibility. *Front. Psychiatry.* **13**, 858238 (2022).
- 656 63. Woodward, E. R. *et al.* Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC 657 in 1514 triple negative familial and isolated breast cancers from a single centre, with extended 658 testing of ATM, RAD51C and RAD51D in over 400. *J. Med. Genet.* (2023).
- 659 64. Stubbins, R. J., Korotev, S. & Godley, L. A. Germline CHEK2 and ATM Variants in Myeloid 660 and Other Hematopoietic Malignancies. *Curr. Hematol. Malig Rep.* **17**, 94-104 (2022).
- 65. Azizi, G. *et al.* The Autoimmune Manifestations in Patients with Genetic Defects in the B Cell 662 Development and Differentiation Stages. *J. Clin. Immunol.* **43**, 819-834 (2023).
- 663 66. Pezone, A. *et al.* Inflammation and DNA damage: cause, effect or both. *Nat. Rev.*664 *Rheumatol.* **19**, 200-211 (2023).
- 665 67. Ghosh, D., Kumari, S. & Raghavan, S. C. Depletion of RNASEH2 Activity Leads to 666 Accumulation of DNA Double-strand Breaks and Reduced Cellular Survivability in T Cell 667 Leukemia. *J. Mol. Biol.* **434**, 167617 (2022).
- 68. Viguera-Elías, D., de la Iglesia-Nagore, I., Toledo-Gotor, C., Domínguez-Garrido, E. & Poch69. Olivé, M. L. Aicardi-Goutieres syndrome: a family case due to alteration of the RNASEH2B
 670 gene. *Rev. Neurol.* 72, 407-409 (2021).
- 671 69. Walia, J. & Mujahid, R. Clinical Disease States Related to Mutations of the NOD2 Gene: A
 672 Case Report and Literature Review. *Cureus* 15, e38584 (2023).
- 70. Priya, B., Ravi, S. & Kirubakaran, S. Targeting ATM and ATR for cancer therapeutics:
 Inhibitors in clinic. *Drug Discov. Today* 28, 103662 (2023).
- 71. Maréchal, A. & Zou, L. DNA damage sensing by the ATM and ATR kinases. *Cold Spring Harb Perspect. Biol.* 5, a012716. doi: 10.1101/cshperspect.a012716 (2013).
- 677 72. Saxena, S. & Zou, L. Hallmarks of DNA replication stress. *Mol. Cell* 82, 2298-2314 (2022).
- 678 73. Paull, T. T. Mechanisms of ATM Activation. Annu. Rev. Biochem. 84, 711-738 (2015).
- 679 74. Lee, J. & Paull, T. T. Activation and regulation of ATM kinase activity in response to DNA
 680 double-strand breaks. *Oncogene* 26, 7741-7748 (2007).
- 681 75. Huang, Y. *et al.* DNAJA2 deficiency activates cGAS-STING pathway via the induction of 682 aberrant mitosis and chromosome instability. *Nat. Commun.* **14**, 5246-0 (2023).
- 683 76. Brown, A. D. *et al.* ATR suppresses endogenous DNA damage and allows completion of 684 homologous recombination repair. *PLoS One* **9**, e91222 (2014).

- 77. McIntyre, R. E. *et al.* Disruption of mouse Cenpj, a regulator of centriole biogenesis,
 phenocopies Seckel syndrome. *PLoS Genet.* 8, e1003022 (2012).
- 687 78. Nagai-Singer, M. A., Morrison, H. A. & Allen, I. C. NLRX1 Is a Multifaceted and Enigmatic 688 Regulator of Immune System Function. *Front. Immunol.* **10**, 2419 (2019).
- 689 79. Chen, L., Cao, S., Lin, Z., He, S. & Zuo, J. NOD-like receptors in autoimmune diseases.
 690 *Acta Pharmacol. Sin.* 42, 1742-1756 (2021).
- 691 80. Liu, M. *et al.* The regulatory role of NLRX1 in innate immunity and human disease. *Cytokine* 692 **160**, 156055 (2022).
- 81. Chu, X., Wu, S. & Raju, R. NLRX1 Regulation Following Acute Mitochondrial Injury. *Front. Immunol.* **10**, 2431 (2019).
- 695 82. Leriche, M. *et al.* 53BP1 interacts with the RNA primer from Okazaki fragments to support 696 their processing during unperturbed DNA replication. *Cell. Rep.* **42**, 113412 (2023).
- 83. Arnould, C. *et al.* Chromatin compartmentalization regulates the response to DNA damage. *Nature* 623, 183-192 (2023).
- 699 84. Vincendeau, E. *et al.* SHLD1 is dispensable for 53BP1-dependent V(D)J recombination but 700 critical for productive class switch recombination. *Nat. Commun.* **13**, 3707-3 (2022).
- 85. Honjoh, H. *et al.* MED1, a novel binding partner of BRCA1, regulates homologous
 recombination and R-loop processing. *Sci. Rep.* **12**, 17140-8 (2022).
- 86. Armstrong, D. L. *et al.* GWAS identifies novel SLE susceptibility genes and explains the
 association of the HLA region. *Genes Immun.* **15**, 347-354 (2014).
- 87. Adam, M. P., Hudgins, L. & Hannibal, M. in *GeneReviews(®)* (ed Adam, M. P. et al.)
 (University of Washington, Seattle. GeneReviews is a registered trademark of the University of
 Washington, Seattle. All rights reserved, Seattle (WA), 1993).
- 88. Dermawan, J. K. *et al.* Distinct genomic landscapes in radiation-associated angiosarcoma
 compared with other radiation-associated sarcoma histologies. *J. Pathol.* 260, 465-477 (2023).
- 89. Zhurinsky, J. *et al.* Effects of the microtubule nucleator Mto1 on chromosomal movement,
 DNA repair, and sister chromatid cohesion in fission yeast. *Mol. Biol. Cell* **30**, 2695-2708 (2019).
- 90. Zhou, C. *et al.* Clinical and genetic analysis of combined oxidative phosphorylation
 defificiency-10 caused by MTO1 mutation. *Clin. Chim. Acta* 526, 74-80 (2022).
- 91. Mushtaq Hashim Al-Bderee, N., Faaz Nassir Al-Saad, N., Jawad Al-Imari, M., Mudhaher
- Habbeb, S. & Mizal Azoz, A. Genetic Polymorphisms of NOD2 and ATG16L1 in Different Types
 of Digestive Tract Inflammation. *Arch. Razi Inst.* **78**, 493-498 (2023).

- 92. Vohhodina, J. *et al.* The RNA processing factors THRAP3 and BCLAF1 promote the DNA
- damage response through selective mRNA splicing and nuclear export. *Nucleic Acids Res.* 45,
 12816-12833 (2017).
- 93. Beli, P. *et al.* Proteomic investigations reveal a role for RNA processing factor THRAP3 in
 the DNA damage response. *Mol. Cell* 46, 212-225 (2012).
- 94. Kumari, N., Antil, H., Kumari, S. & Raghavan, S. C. Deficiency of ligase IV leads to reduced
 NHEJ, accumulation of DNA damage, and can sensitize cells to cancer therapeutics. *Genomics*115, 110731 (2023).
- 95. Jauch, A. J. *et al.* Autoimmunity and immunodeficiency associated with monoallelic LIG4
 mutations via haploinsufficiency. *J. Allergy Clin. Immunol.* **152**, 500-516 (2023).
- 96. Yilmaz Demirdag, Y. & Gupta, S. Infections in DNA Repair Defects. *Pathogens* 12, 440. doi:
 10.3390/pathogens12030440 (2023).
- 97. Ramirez, N. *et al.* Multi-omics analysis of naïve B cells of patients harboring the C104R
 mutation in TACI. *Front. Immunol.* **13**, 938240 (2022).
- 98. Kakkas, I. *et al.* TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in
 Greece. *Medicina (Kaunas)* 57, 827. doi: 10.3390/medicina57080827 (2021).
- 99. de Valles-Ibáñez, G. *et al.* Evaluating the Genetics of Common Variable Immunodeficiency:
 Monogenetic Model and Beyond. *Front. Immunol.* 9, 636 (2018).
- 100. Nomani, H. *et al.* Implications of combined NOD2 and other gene mutations in
 autoinflammatory diseases. *Front. Immunol.* 14, 1265404 (2023).
- 101. Karamanakos, A. *et al.* Autoinflammatory syndromes with coexisting variants in
- 738 Mediterranean FeVer and other genes: Utility of multiple gene screening and the possible 739 impact of gene dosage. *Semin. Arthritis Rheum.* **56**, 152055 (2022).
- 740 102. Wouters, F., Bogie, J., Wullaert, A. & van der Hilst, J. Recent Insights in Pyrin
- Inflammasome Activation: Identifying Potential Novel Therapeutic Approaches in Pyrin Associated Autoinflammatory Syndromes. J. Clin. Immunol. 44, 8-5 (2023).
- 103. Nomani, H. *et al.* Implications of combined NOD2 and other gene mutations in
 autoinflammatory diseases. *Front. Immunol.* 14, 1265404 (2023).
- 104. Hao, Q., Lu, H. & Zhou, X. A potential synthetic lethal strategy with PARP inhibitors:
- perspective on 'Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP'. J. Mol. *Cell. Biol.* 13, 690-692 (2021).
- 105. Huang, R. *et al.* The p53/RMRP/miR122 signaling loop promotes epithelial-mesenchymal
 transition during the development of silica-induced lung fibrosis by activating the notch pathway. *Chemosphere* 263, 128133 (2021).

- 106. Wolf, C. *et al.* UNC93B1 variants underlie TLR7-dependent autoimmunity. *Sci. Immunol.*,
 eadi9769 (2024).
- 107. He, Z., Ye, S., Xing, Y., Jiu, Y. & Zhong, J. UNC93B1 curbs cytosolic DNA signaling by promoting STING degradation. *Eur. J. Immunol.* **51**, 1672-1685 (2021).
- 108. Zhu, H., Zhang, R., Yi, L., Tang, Y. & Zheng, C. UNC93B1 attenuates the cGAS-STING
 signaling pathway by targeting STING for autophagy-lysosome degradation. *J. Med. Virol.* 94,
 4490-4501 (2022).
- 109. Ciążyńska, M. *et al.* The Role of NLRP1, NLRP3, and AIM2 Inflammasomes in Psoriasis:
 Review. *Int. J. Mol. Sci.* 22, 5898. doi: 10.3390/ijms22115898 (2021).
- 110. Docherty, C. A. *et al.* A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the
 treatment of inflammatory diseases. *Clin. Transl. Immunology* **12**, e1455 (2023).
- 111. Miyashita, Y. *et al.* TICAM-1/TRIF associates with Act1 and suppresses IL-17 receptormediated inflammatory responses. *Life. Sci. Alliance* 5, e202101181. doi:
 10.26508/lsa.202101181. Print 2022 Feb (2021).
- 112. Jensen, L. T., Attfield, K. E., Feldmann, M. & Fugger, L. Allosteric TYK2 inhibition:
 redefining autoimmune disease therapy beyond JAK1-3 inhibitors. *EBioMedicine* **97**, 104840
 (2023).
- 113. Gevezova, M. *et al.* Autistic spectrum disorder (ASD) Gene, molecular and pathway
 signatures linking systemic inflammation, mitochondrial dysfunction, transsynaptic signalling,
 and neurodevelopment. *Brain Behav. Immun. Health.* **30**, 100646 (2023).
- 114. Pollina, E. A. *et al.* A NPAS4-NuA4 complex couples synaptic activity to DNA repair. *Nature* 614, 732-741 (2023).
- 115. Zhou, X. *et al.* Integrating de novo and inherited variants in 42,607 autism cases identifies
 mutations in new moderate-risk genes. *Nat. Genet.* 54, 1305-1319 (2022).
- 116. Wilfert, A. B. *et al.* Recent ultra-rare inherited variants implicate new autism candidate risk
 genes. *Nat. Genet.* 53, 1125-1134 (2021).
- 117. Fu, J. M. *et al.* Rare coding variation provides insight into the genetic architecture and
 phenotypic context of autism. *Nat. Genet.* 54, 1320-1331 (2022).
- 118. Mueller, F. S. *et al.* Deficient DNA base-excision repair in the forebrain leads to a sexspecific anxiety-like phenotype in mice. *BMC Biol.* 20, 170-1 (2022).
- 119. Shen, X. *et al.* The role of Gadd45b in neurologic and neuropsychiatric disorders: An
 overview. *Front. Mol. Neurosci.* **15**, 1021207 (2022).
- 120. Dileep, V. *et al.* Neuronal DNA double-strand breaks lead to genome structural variations
 and 3D genome disruption in neurodegeneration. *Cell* **186**, 4404-4421.e20 (2023).

- 121. Yang, C. *et al.* Expression signature of inflammation-associated long non-coding RNAs in adult-onset Still's disease. *Clin. Exp. Rheumatol.* **39 Suppl 132**, 67-74 (2021).
- 122. Jaber, S., Toufektchan, E., Lejour, V., Bardot, B. & Toledo, F. p53 downregulates the
 Fanconi anaemia DNA repair pathway. *Nat. Commun.* 7, 11091 (2016).
- 123. Rakotopare, J. & Toledo, F. p53 in the Molecular Circuitry of Bone Marrow Failure
 Syndromes. *Int. J. Mol. Sci.* 24, 14940. doi: 10.3390/ijms241914940 (2023).
- 124. Parvin, S. *et al.* ATM depletion induces proteasomal degradation of FANCD2 and
 sensitizes neuroblastoma cells to PARP inhibitors. *BMC Cancer* 23, 313-y (2023).
- 125. Ishiai, M. Regulation of the Fanconi Anemia DNA Repair Pathway by Phosphorylation and
 Monoubiquitination. *Genes (Basel)* 12, 1763. doi: 10.3390/genes12111763 (2021).
- 126. Tammimies, K. Genetic mechanisms of regression in autism spectrum disorder. *Neurosci. Biobehav. Rev.* 102, 208-220 (2019).
- 127. Golla, S. & Sweeney, J. A. Corticosteroid therapy in regressive autism: Preliminary findings
 from a retrospective study. *BMC Med.* 12, 79-79 (2014).
- 128. Rossignol, D. A. & Frye, R. E. A Systematic Review and Meta-Analysis of Immunoglobulin
 G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism
 Spectrum Disorder. *J. Pers. Med.* **11**, 488. doi: 10.3390/jpm11060488 (2021).
- 129. Hopfner, K. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING
 signalling. *Nat. Rev. Mol. Cell Biol.* 21, 501-521 (2020).
- 130. Phelan, T., Little, M. A. & Brady, G. Targeting of the cGAS-STING system by DNA viruses. *Biochem. Pharmacol.* **174**, 113831 (2020).
- 131. Fan, Y. M., Zhang, Y. L., Luo, H. & Mohamud, Y. Crosstalk between RNA viruses and DNA
 sensors: Role of the cGAS-STING signalling pathway. *Rev. Med. Virol.* 32, e2343 (2022).
- 808 132. Wang, C. *et al.* Ultrasound-responsive low-dose doxorubicin liposomes trigger
 809 mitochondrial DNA release and activate cGAS-STING-mediated antitumour immunity. *Nat.*810 *Commun.* 14, 3877-x (2023).
- 133. Kim, J., Kim, H. & Chung, J. H. Molecular mechanisms of mitochondrial DNA release and
 activation of the cGAS-STING pathway. *Exp. Mol. Med.* 55, 510-519 (2023).
- 813 134. West, A. P. *et al.* Mitochondrial DNA stress primes the antiviral innate immune response.
 814 *Nature* 520, 553-557 (2015).
- 135. Lammert, C. R. *et al.* AIM2 inflammasome surveillance of DNA damage shapes
 neurodevelopment. *Nature* 580, 647-652 (2020).
- 136. Dawson, R. E. *et al.* The cytosolic DNA sensor AIM2 promotes Helicobacter-induced gastric pathology via the inflammasome. *Immunol. Cell Biol.* **101**, 444-457 (2023).

- 819 137. Vinuesa, C. G., Grenov, A. & Kassiotis, G. Innate virus-sensing pathways in B cell
 820 systemic autoimmunity. *Science* 380, 478-484 (2023).
- 138. Hu, Y. *et al.* Emerging role of the cGAS-STING signaling pathway in autoimmune
 diseases: Biologic function, mechanisms and clinical prospection. *Autoimmun. Rev.* 21, 103155
 (2022).
- 139. Kivanc, D. & Dasdemir, S. The relationship between defects in DNA repair genes and autoinflammatory diseases. *Rheumatol. Int.* **42**, 1-13 (2022).
- 140. Miner, J. J. & Fitzgerald, K. A. A path towards personalized medicine for autoinflammatory
 and related diseases. *Nat. Rev. Rheumatol.* **19**, 182-189 (2023).
- 141. Li, R. *et al.* cGAS/STING signaling in the regulation of rheumatoid synovial aggression.
 Ann. Transl. Med. **10**, 431-4533 (2022).
- 142. Hagiwara, A. M., Moore, R. E., Wallace, D. J., Ishimori, M. & Jefferies, C. A. Regulation of
 cGAS-STING Pathway Implications for Systemic Lupus Erythematosus. *Rheumatol. Immunol. Res.* 2, 173-184 (2021).
- 143. Wobma, H., Shin, D. S., Chou, J. & Dedeoğlu, F. Dysregulation of the cGAS-STING
 Pathway in Monogenic Autoinflammation and Lupus. *Front. Immunol.* **13**, 905109 (2022).
- 144. lourov, I. Y. *et al.* Causes and Consequences of Genome Instability in Psychiatric and
 Neurodegenerative Diseases. *Mol. Biol. (Mosk)* 55, 42-53 (2021).
- 145. Loncharich, M. F. & Anderson, C. W. Interferon Inhibition for Lupus with Anifrolumab:
 Critical Appraisal of the Evidence Leading to FDA Approval. *ACR Open Rheumatol.* 4, 486-491
 (2022).
- 840 146. Weckerle, C. E. *et al.* Network analysis of associations between serum interferon-α activity,
 841 autoantibodies, and clinical features in systemic lupus erythematosus. *Arthritis Rheum.* 63,
 842 1044-1053 (2011).
- 147. Nikolaidou, A., Beis, I., Dragoumi, P. & Zafeiriou, D. Neuropsychiatric manifestations
 associated with Juvenile Systemic Lupus Erythematosus: An overview focusing on early
 diagnosis. *Brain Dev.* (2023).
- 148. Van der Heijden, H. *et al.* Implications of Inflammatory Processes on a Developing Central
 Nervous System in Childhood-onset Systemic Lupus Erythematosus. *Arthritis Rheumatol.*(2023).
- 149. Ferecskó, A. S. *et al.* STING-Triggered CNS Inflammation in Human Neurodegenerative
 Diseases. *Biomedicines* 11, 1375. doi: 10.3390/biomedicines11051375 (2023).
- 150. Gulen, M. F. *et al.* cGAS-STING drives ageing-related inflammation and neurodegeneration. *Nature* **620**, 374-380 (2023).

- 151. Chen, K. *et al.* cGAS-STING-mediated IFN-I Response in Host Defense and Neuroinflammatory Diseases. *Curr. Neuropharmacol.* **20**, 362-371 (2022).
- 152. Beesetti, S. *et al.* FANCL supports Parkin-mediated mitophagy in a ubiquitin ligaseindependent manner. *Biochim. Biophys. Acta Mol. Basis Dis.* **1868**, 166453 (2022).
- 153. Luzwick, J. W. *et al.* MRE11-dependent instability in mitochondrial DNA fork protection
 activates a cGAS immune signaling pathway. *Sci. Adv.* 7, eabf9441 (2021).
- 154. Habibi, P. *et al.* Effect of heat stress on DNA damage: a systematic literature review. *Int. J. Biometeorol.* 66, 2147-2158 (2022).
- 155. Couillin, I. & Riteau, N. STING Signaling and Sterile Inflammation. *Front. Immunol.* 12,
 753789 (2021).
- 156. Yang, J. *et al.* STING in tumors: a focus on non-innate immune pathways. *Front. Cell. Dev. Biol.* **11**, 1278461 (2023).
- 157. He, X. *et al.* IUPHAR ECR review: The cGAS-STING pathway: novel functions beyond
 innate immune and emerging therapeutic opportunities. *Pharmacol. Res.*, 107063 (2024).
- 158. Xun, J. *et al.* A conserved ion channel function of STING mediates noncanonical
 autophagy and cell death. *EMBO Rep.* (2024).
- 869

870 Acknowledgments

- 871 H.M.L. is supported by the National Institute of Child Health and Human Development
- 872 NIH/NICHD; P30 HD071593 to the Albert Einstein College of Medicine's Rose F. Kennedy
- 873 Intellectual and Developmental Disabilities Research Center, and the National Institute of
- 874 Mental Health, R21MH131740. The Lachman lab also receives support from the Janice C.
- 875 Blanchard Family Fund and the iPS Cell Research for Ryan Stearn Fund. This work was funded
- by grants to the J.L.C Swedish Research Council (Grant No. 2019-06082). P.J. van der Spek is
- supported by EU H2020 grants, an ImmunAID grant (ID: 7792950), and a
- 878 MOODSTRATIFICATION grant (ID: 754740). The Bioinformatics infrastructure and team are
- 879 supported by grants from KWF, NWO/ZonMW, and the Dutch Heart Foundation through the
- 880 BDVA-initiated H2020 Bigmedilytics program on Personalized Medicine. Janet Cunningham is a
- 881 Gullstrand Fellow at Uppsala University Hospital. Jennifer Frankovich's research is supported
- by several foundations including the Neuroimmune Foundation, Lucile Packard Foundation for
- 883 Children's Health, the Dollinger Biomarker Core, Stanford Spark, and collaborations on NIH
- grants. Funders had no role in study design, data collection and analysis, decision to publish, or
- 885 preparation of the manuscript. We thank the Albert Einstein College of Medicine Epigenomics

Shared Core Facility RRID: SCR_023284 for Library preparation, QC, and sequencing, and
Yongmei Zhao for technical assistance with the library preps. The authors want to thank the
participating families.

889

890 Author contributions

891 J.L.C. co-wrote the paper, and was involved in the study concept and design; J.F. contributed 892 cases, provided genetic data for case 16, and co-wrote the manuscript); R,A.B. carried out 893 WES on case 10); E.P. processed DNA, validated variants, edited manuscript, created figures 894 1,3; R.F.A. validated variants; N.C.S. contributed case 16; S.B.M. made the WES library for 895 case 10; H.D. involved in study concept; J.M. validated variants); J.E. validated variants; J.M.S. 896 validated variants carried out Alphamissense analysis; G.L. contributed case 1, edited 897 manuscript); S.M.A.S. bioinformatics of variants, created Figure 4; S.S. edited manuscript; 898 P.J.S. study concept and design, bioinformatics; H.M.L.co-wrote paper, study concept and 899 design, analyzed variants, confirmed diagnoses, supervised study. All authors reviewed the 900 manuscript.

901

902 Data availability statement

903 Variants reported in this paper will be submitted to ClinVar. WES data on case 10 will be made904 available at GenBank ®

905

906 Competing interests

907 J.L.C. has received lecturing fees from Otsuka Pharma Scandinavia, Janssen-Cilag AB and H.908 Lundbeck AB.

909

910 Figure Legends

Figure 1. p53 DNA repair pathway. A simplified depiction showing the regulation of p53 tumor
suppressor activity by phosphorylation triggered by ATM, ATR, CHK1, and CHK2 kinases, and
dephosphorylation by PPM1D. P53 activation can induce apoptosis or cell cycle arrest, which
will eliminate DNA-damaged cells or provide an opportunity to repair the damage, respectively.
Loss of function mutations in *ATM* or gain of function mutations in *PPM1D*, such as those found
in patients with acute neuropsychiatric decompensation in cases 1-7, would be expected to lead
to a decrease in p53 activity.

Figure 2. Fanconi Core Complex. The Fanconi Core Complex of proteins repairs interstrand
crosslink breaks (Figure adapted from reference 49). The letters are abbreviations for the

- 920 Fanconi complex proteins (i.e., "A" is FANCA; "E" is FANCE, etc.). Monoubiquitinated (Ub)
- 921 FANCD2 and FANCI form a dimer that binds to crosslink repair sites, which leads to the
- 922 recruitment of nucleases that repair the DNA lesion (reference 53). All of the Fanconi complex
- genes described in this paper are depicted in bold type (FANCE, SLX4, FANCE, and FANCA).
- 924 Interactions between Fanconi proteins with ATM/ATR are shown. The image was generated
- 925 using biorender https://www.biorender.com/).
- 926 Figure 3. Protein-Protein Interaction Network: STRING. A connectivity network was
- generated for the candidate genes using IPA software. Central to the network are ATM and p53.
- 928 Genes described in the paper that do not fit into the connectivity network are not shown (C7,
- 929 DBH, SLC13AS, SRPK3, NLRX1, MTO1, CACNA1H, CACNA1S, CLPB, AHNAK2). SLX4 =
- 930 FANCA/SLX4, TP53=p53, and TP53BP1 = 53BP1.
- 931 Supplementary Data
- 932 Supplementary Methods. An expanded description of the methods and primers used for933 Sanger DNA sequencing.
- 934 **Supplementary Table**. Description of additional gene variants found upon whole exome
- 935 sequencing or the analysis of gene panels.
- 936 Supplementary Figure. RMRP secondary structures. The RNAfold web server was used to
- 937 predict secondary structures for wild-type and mutant (c. C126T) RMRP RNAs. Differences
- 938 between the two, especially in the centroid secondary structures, are seen.







Case	Family	Age*	Gene	Dx	Variant	Туре	CADD	ClinVar	Alpha Missense	Inheritance	MAF	Map position hg38	rs number	Additional rare and ultrarare variants	Genome sequencing	valida tion,
1	N/A	16-20	PPM1D	JdVS, AR, PANS	c.1535delA; p.Asn512fsXs	fra mesh ift	N/A	pathogenic	N/A	de novo	0.00002	c hr17:60663013	rs763475304	CSNK1a1, SRPK3, SLC13A5, CACNA1S	GeneDx WES	yes
2	N/A	6 to 10	PPM1D	JdVS, AR	c.1573G>T; p.Glu525Ter	nonsense	39	uncertain significance	N/A	de novo	7 E-06	chr17:60663307	rs759850701	no ne re ported	NHS North West NDD panel	no
3	N/A	11 to 15	AT M	PANS	c.7517_7520 del; p.Arg25061	fra mesh ift	N/A	pathogenic	N/A	pa re nt	8 E-0 6	chr11:108331342-108331548	s rs587781905	CAC NA1H, AHNAK2	Balor Genetics WES	no
4	1	6 to 10	AT M	ASD, AR, PANS	c.8418+5_8418+8delGTGA	splice do no r	N/A	pa thoge nic	N/A	pa re nt	4 E-0 6	chr11:108343272-108343479	rs730881295	RNASEH2B, RAG2, C7, NO D2, SP110	Invitae Immunodeficiency Panel	yes
5	1	11 to 15	AT M	ASD, AR, PANS	c.8418+5_8418+8delGTGA	splice do no r	N/A	pa tho ge nic	N/A	pa re nt	4 E-0 6	chr11:108343272-108343479	rs730881295	RNASEH2B, RAG2, NO D2 rs529640892	Sanger sequencing of case 4 variants	yes
6	1	6 to 10	AT M	ASD, AR, PANS	c.8418+5_8418+8delGTGA	splice do no r	N/A	pa tho ge nic	N/A	pa re nt	4 E-0 6	chr11:108343272-108343479	rs730881295	RNASEH2B, C7, NO D2 rs529640892	GeneDx WES	yes
7	1	6 to 10	AT M	ASD, AR, PANS	c.8418+5_8418+8delGTGA	splice do no r	N/A	pathogenic	N/A	pa re nt	4 E-0 6	chr11:108343272-108343479	rs730881295	RAG2, NOD2 rs 140716236 , S P110	Sanger sequencing of case 4 variants	yes
8	2	0-5	ATR	ASD, PANS AE	c.2507A>T; p.Asp836Val	missense	24	not found	benign, 0.095	pa re nt	u n know n	chr3:142,553,850	novel	CENPI, NLRX1, DBH, CACNA1S, CLPB	Courtagen Diagnostics Laboratory WES	yes
9	2	0-5	ATR	ASD, PANS, AR	c.2507A>T; p.Asp836Val	missense	24	not found	benign, 0.095	pa re nt	u n k no w n	chr3:142,553,850	novel	CENPJ, NLRX1, DBH, CACNA1S, CLPB	Courtagen Diagnostics Laboratory WES	yes
10	N/A	0-5	53 B P1	DD, AR, PANS	c.G3307T; p.Asp1103Tyr	missense	21.7	not found	benign, 0.1176	u n know n	0.00002	ch r 15 x 3 4 3 2 4 6 2	rs551038749	MED1, KMT2 D, MTO 1	Einstein Epigenetics Shared Facility WES	yes
11	3	0-5	FANCE	CVID, PANS	c.127G>A; p.Gly43Ser	missense	23.1	uncerta in significance	ambigous, 0 4 766	pa re nt	u n k no w n	ch r6:35452572	rs892819655	VPS13 B	Invitae Im munodeficiency Panel	yes
12	3	0-5	FANCE	CVID, DD, AE	c.127G>A; p.G ly43Ser	m issense	23.1	uncertain significance	ambigous, 0 A 766	pare nt	u n k no w n	ch r6:35452572	rs892819655	VPS13 B, THRAP3, NO D2	Invitae Immunodeficiency Panel	yes
13	N/A	11 to 15	FANCI	AE, PANS	c.1461T>A; p.Tyr487Ter	n o ns e nse	37	pathogenic/likely pathogenic	N/A	un know n	0.00003	chr15:89281149	rs769248873	FA NC P/SLX4, LIG4	Invitae Immunodeficiency Panel	no
14	4	6 to 10	FANC P	CVID, PANS, AE	c.2623 G>A; p.G lu875Lys	missense	14.15	not found	benign, 0.0771	un know n	1.6E-05	chr16:3590914	rs924446221	RMRP, MEFV, TNFRSF13B, DOCK8	Invitae Immunodeficiency Panel	no
15	4	6 to 10	FANC P	CVID, AE	c.2623 G>A; p.G lu875Lys	missense	14.15	not found	benign, 0.0771	u n know n	1.6E-05	chr16:3590914	rs924446221	RMRP, MEFV, TNFRSF13B, DOCK8	Invitae Immunodeficiency Panel	no
16	N/A	6 to 10	FANCA	PANS	c.1771C>G; p.Arg591Gly	m issens e	21.9	uncertain significance	pathogenic, 0.6394	un know n	0.00006	chr16:89778848	rs753980264	UNC93B1, NLRP1, TICA M1, TYK2, TC N2	In vitae Im m u nodeficien cyand Ciliary Dysk in esia Pan els	no

Table. Description of all primary DNA repair variants. *Age range at diagnosis; Dx: diagnosis (JdVS: Jansen de Vries Syndrome, AR: acute regression, PANS: pediatric acute-onset neuropsychiatric syndrome, AE: autoimmune encephalitis, DD: developmental delay, CVID: common variable immune deficiency); variant shows the cDNA and amino acid changes; type shows how the mutation affects gene function; CADD: Combined Annotation score; N/A not available. ClinVar is the predicted pathogenicity based on the ClinVar database; AlphaMissense is the predicted pathogenicity based on amino acid change (see main text); Inheritance pattern shows that the variant in question was either de novo or transmitted from a parent. The sex of the parent was omitted to maintain anonymity; MAF: Minor allele frequency; Map position shows coordinates of variants based on hg38 build; rs number is based on SNP database; Additional variants were found in each case (see Supplemental table for descriptions; Genome sequencing shows the genetic analysis that was carried out; validation by Sanger sequencing